T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Velasquez, Mireya Paulina ^a,b   Torres, David ^a,b   Iwahori, Kota ^a,b   Kakarla, Sunitha ^a,b   Arber, Caroline ^a,b   Rodriguez Cruz, Tania ^a,b   Szoor, Arpad ^a,b   Bonifant, Challice L ^a,b   Gerken, Claudia ^a,b   Cooper, Laurence J N ^c   Song, Xiao Tong ^a,b   Gottschalk, Stephen ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD19 MOLECULE, HUMAN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

A-549 CELL LINE; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL; CYTOLOGY; CYTOTOXICITY; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; K-562 CELL LINE; METABOLISM; MOUSE; T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE;

A549 CELLS; ANIMALS; ANTIGENS, CD19; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; K562 CELLS; MICE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84973352594     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27130     Document Type: Article

References (41)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA.Cancer J.Clin. 63, 11-30 (2013).
2. Annesley, C. E. & Brown, P. Novel agents for the treatment of childhood acute leukemia. Therapeutic advances in hematology 6, 61-79 (2015).
3. Pui, C. H., Mullighan, C. G., Evans, W. E. & Relling, M. V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120, 1165-1174 (2012).
4. DeAngelo, D. J. et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29, 526-534 (2015).
5. Armenian, S. H., Landier, W., Hudson, M. M., Robison, L. L. & Bhatia, S. Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes. Pediatr.Blood Cancer 60, 1063-1068 (2013).
6. Handgretinger, R. et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 25, 181-184 (2011).
7. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N.Engl.J.Med. 371, 1507-1517 (2014).
8. Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl.Med. 6, 224ra225 (2014).
9. Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528 (2015).
10. Baeuerle, P. A., Kufer, P. & Bargou, R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr.Opin.Mol.Ther. 11, 22-30 (2009).
11. Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 321, 974-977 (2008).
12. Topp, M. S. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J.Clin.Oncol. 29, 2493-2498 (2011).
13. Klinger, M. et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119, 6226-6233 (2012).
14. Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16, 57-66 (2015).
15. Stieglmaier, J., Benjamin, J. & Nagorsen, D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert opinion on biological therapy 15, 1093-1099 (2015).
16. Reichert, J. M. Antibodies to watch in 2015. MAbs. 7, 1-8 (2015).
17. Sanford, M. Blinatumomab: first global approval. Drugs 75, 321-327 (2015).
18. Frankel, S. R. & Baeuerle, P. A. Targeting T cells to tumor cells using bispecific antibodies. Curr.Opin.Chem.Biol. 17, 385-392 (2013).
19. Fournier, P. & Schirrmacher, V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs. 27, 35-53 (2013).
20. Compte, M. et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther. 14, 380-388 (2007).
21. Iwahori, K. et al. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 23, 171-178 (2015).
22. Shaffer, D. R. et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117, 4304-4314 (2011).
23. Arber, C. et al. Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest 125, 157-168 (2015).
24. Nicholson, I. C. et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol.Immunol. 34, 1157-1165 (1997).
25. Damschroder, M. M. et al. Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol.Immunol. 44, 3049-3060 (2007).
26. Chow, K. K. et al. T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. Mol.Ther. 21, 629-637 (2013).
27. Jena, B. et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLos. One. 8, e57838 (2013).
28. Dotti, G., Gottschalk, S., Savoldo, B. & Brenner, M. K. Design and development of therapies using chimeric antigen receptorexpressing T cells. Immunol Rev. 257, 107-126 (2014).
29. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat.Rev. Immunol. 12, 269-281 (2012).
30. Meager, A. Measurement of cytokines by bioassays: theory and application. Methods 38, 237-252 (2006).
31. Stephan, M. T. et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440-1449 (2007).
32. Muller, D., Frey, K. & Kontermann, R. E. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J.Immunother. 31, 714-722 (2008).
33. Davila, M. L., Kloss, C. C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLos.One. 8, e61338 (2013).
34. Dreier, T. et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J.Immunol. 170, 4397-4402 (2003).
35. Cheadle, E. J. et al. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J.Immunother. 32, 207-218 (2009).
36. Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P. & Rosenberg, S. A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875-3886 (2010).
37. Teachey, D. T. et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154-5157 (2013).
38. Hoyos, V. et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/ leukemia effects and safety. Leukemia 24, 1160-1170 (2010).
39. Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133-4141 (2012).
40. Quintarelli, C. et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110, 2793-2802 (2007).
41. Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N.Engl.J.Med. 365, 1673-1683 (2011).